VTCN1 and glioblastoma: Yao et al.’s phase II trial using dendritic cell vaccines loaded with GBM stem cell-like antigens demonstrated improved survival, with B7-H4-low expressing patients showing significantly better OS, indicating B7-H4 as a new target for glioma immunotherapy (54).